Advertisement

Combinations of Cytotoxic Drugs, Ionizing Radiation and EGFR Inhibitors

  • Guido Lammering
Chapter
Part of the Medical Radiology book series (MEDRAD)

Keywords

Epidermal Growth Factor Receptor Radiat Oncol Biol Phys Epidermal Growth Factor Receptor Inhibitor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epidermal Growth Factor Receptor Overexpression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akimoto T, Hunter NR, Buchmiller L, Mason KA, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884–2890PubMedGoogle Scholar
  2. Ang KK, Andratschke NH, Milas L (2004) Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58:959–965PubMedCrossRefGoogle Scholar
  3. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T (1996) The effect of Ionizing radiation on signal transduction: antibodies to EGF receptors sensitise A431 cells to radiation. Biochim Biophys Acta 1314:147–156PubMedCrossRefGoogle Scholar
  4. Baselga J, Mendelsohn J (1994) The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127–138PubMedCrossRefGoogle Scholar
  5. Baumann M, Krause M, Zips D, Eicheler W, Doerfler A, Ahrens J, Petersen C, Bruechner K, Hilberg F (2003) Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 79:547–559PubMedCrossRefGoogle Scholar
  6. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Bohlen P, Raisch KP (2002) Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine and radiation. Int J Radiat Oncol Biol Phys 54:1180–1193PubMedCrossRefGoogle Scholar
  7. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328–3335PubMedGoogle Scholar
  8. Ciardiello F, Bianco R, Damiano V, Lorenzo S de, Pepe S, Placido S de, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumour activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909–916PubMedGoogle Scholar
  9. Contessa JN, Reardon DB, Todd D, Dent P, Mikkelsen RB, Valerie K, Bowers GD, Schmidt-Ullrich RK (1999) The inducible expression of dominant negative epidermal growth factor receptor CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 5:405–411PubMedGoogle Scholar
  10. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G (2005) Cooperative antitumour effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11:5639–5644PubMedCrossRefGoogle Scholar
  11. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182–31189PubMedCrossRefGoogle Scholar
  12. Earp HS, Dawson TL, Li X, Yu H (1995) Heterodimerization and functional interaction between EGF Receptor Family Members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115–132PubMedCrossRefGoogle Scholar
  13. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW (2005) Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56:155–162PubMedGoogle Scholar
  14. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17:613–620PubMedGoogle Scholar
  15. Fowler JF (1991) Rapid repopulation in radiotherapy; a debate on mechanism. The phantom of tumour treatment: continually rapid proliferation unmasked. Radiother Oncol 22:156–158PubMedCrossRefGoogle Scholar
  16. Fox SB, Gatter KC, Harris AL (1996) Tumour angiogenesis. J Pathol 179:232–237PubMedCrossRefGoogle Scholar
  17. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Bridges AJ (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093–1095PubMedGoogle Scholar
  18. Giocanti N, Hennequin C, Rouillard D, Defrance R, Favaudon V (2004) Additive interaction of gefitinib (“Iressa”, ZD1839) and Ionizing radiation in human tumour cells in vitro. Br J Cancer 91:2026–2033PubMedCrossRefGoogle Scholar
  19. Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S, Torres I de (2002) Epidermal growth factor receptor is a predictor of tumour response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:1460–1465PubMedCrossRefGoogle Scholar
  20. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin Cancer Res 1:1311–1318PubMedGoogle Scholar
  21. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  22. Harari PM, Huang SM (2001) Radiation response modification following molecular inhibition of epidermal growth factor receptor signalling. Semin Radiat Oncol 11:281–289PubMedCrossRefGoogle Scholar
  23. Harari PM, Huang SM (2002) Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 12:21–26PubMedCrossRefGoogle Scholar
  24. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GL, Wiley HS, Cavenee WK (1997) The enhanced tumourigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927–2935PubMedCrossRefGoogle Scholar
  25. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumour angiogenesis. Clin Cancer Res 6:2166–2174PubMedGoogle Scholar
  26. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935–1940PubMedGoogle Scholar
  27. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumour-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62:4300–4306PubMedGoogle Scholar
  28. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874–4884PubMedGoogle Scholar
  29. Kashles O, Yarden Y, Fisher R, Ullrich A, Schlessinger J (1991) A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 11:1454–1463PubMedGoogle Scholar
  30. Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M (2005) Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 74:109–115PubMedCrossRefGoogle Scholar
  31. Lammering G, Hewit TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK (2001) Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93:921–929PubMedCrossRefGoogle Scholar
  32. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G (2002) Sequence-dependent effects of ZD1839 (“Iressa”) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86:819–827PubMedCrossRefGoogle Scholar
  33. Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703–2707PubMedGoogle Scholar
  34. Mendelsohn J, Fan Z (1997) Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89:341–343PubMedCrossRefGoogle Scholar
  35. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang KK, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708PubMedGoogle Scholar
  36. Modjtahedi H, Affleck K, Stubberfield C, Dean C (1998) EGFR blockade by tyr kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in human squamous cell carcinoma HN5. Int J Oncol 13:335–342PubMedGoogle Scholar
  37. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 55:5536–5539PubMedGoogle Scholar
  38. Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L (2004) C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163–1173PubMedCrossRefGoogle Scholar
  39. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, Lawrence TS (2004) Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10:691–700PubMedCrossRefGoogle Scholar
  40. Ogawa J, Iwazaki M, Inoue H, Koide S, Shohtsu A (1993) Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin-sensitivity. Cancer 71:2204–2209PubMedCrossRefGoogle Scholar
  41. Pao W, Miller V, Zakowski M, Doherty J, Ploiti K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311PubMedCrossRefGoogle Scholar
  42. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG (2005) Treatment of human tumour xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumour activity. Clin Cancer Res 11:6390–6399PubMedCrossRefGoogle Scholar
  43. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257–265PubMedGoogle Scholar
  44. Pillai M, Jayaprakash PG, Nair M (1998) Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 124:456–461PubMedCrossRefGoogle Scholar
  45. Raben D, Helfrich B, Chan D, Shogun T, Zundel W, Scafani R, Bunn P (2001) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Clin Cancer Res 7:3805–3809Google Scholar
  46. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK, Bunn PA Jr (2005) The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11:795–805PubMedGoogle Scholar
  47. Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519–1528PubMedCrossRefGoogle Scholar
  48. Reardon DR, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK (1999) Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18:4756–4766PubMedCrossRefGoogle Scholar
  49. Redemann N, Holzmann B, Rueden TV, Wagner EF, Ullrich A (1992) Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 12:491–498PubMedGoogle Scholar
  50. Riese DJ II, Stern DF (1998) Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41–48PubMedCrossRefGoogle Scholar
  51. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ (1997) EGFR dependent regulation of keratinocyte survival. J Cell Sci 110:113–121PubMedGoogle Scholar
  52. Saleh MN, Raisch KP, Stackhouse MA (1999) Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14:451–463PubMedCrossRefGoogle Scholar
  53. Santini J, Formento J-L, Francoual M, Milano G, Schneider M, Dassonville O, Demard F (1991) Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132–139PubMedGoogle Scholar
  54. Schmidt-Ullrich RK, Valerie K, Chan W, McWilliams D (1994) Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29:813–819PubMedGoogle Scholar
  55. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J (1996) Radiation-induced auto-phosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145:79–83Google Scholar
  56. Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K (1999) Signal transduction and cellular radiation responses. Radiat Res 153:245–257CrossRefGoogle Scholar
  57. Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino GP (2003) Receptor tyrosine kinases and cellular responses to Ionizing radiation. Oncogene Rev 22:5855–5865CrossRefGoogle Scholar
  58. Sihto H, Puputti M, Pulli L, Tynninen O, Koskinen W, Aaltonen LM, Tanner M, Bohling T, Visakorpi T, Butzow R, Knuuttila A, Nupponen NN, Joensuu H (2005) Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumours. J Mol Med epubGoogle Scholar
  59. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C (2003) EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumour effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 55:713–723PubMedCrossRefGoogle Scholar
  60. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ, Martinez JD (2003) Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (“Iressa”). Cancer Lett 202:43–51PubMedCrossRefGoogle Scholar
  61. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK (2005) Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 280:14597–14604PubMedCrossRefGoogle Scholar
  62. Tanaka T (2005) Inhibition of DNA repair in the radiosensitization of NSCLC cells by gefitinib, a specific EGFR-inhibitor. Proc Am Assoc Cancer Res 46:abstract 1994Google Scholar
  63. Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP (2005) Radioresistance of K-Ras mutated human tumour cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 76:143–150PubMedCrossRefGoogle Scholar
  64. Weinberg RA (1989) Oncogenes and the molecular origin of cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp 54–62Google Scholar
  65. Wells A (2000) The epidermal growth factor receptor (EGFR): a new target in cancer therapy. Signal 1:4–11Google Scholar
  66. Wikstrand CJ, McLendon RE, Friedman AH, Bigner AD (1997) Cell surface localization and density of the tumour-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130–4140PubMedGoogle Scholar
  67. Williams KJ, Telfer BA, Stratford IJ, Wedge S (2002) ZD1839 (“Iressa”), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157–1161PubMedCrossRefGoogle Scholar
  68. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumour activity. Clin Cancer Res 10:8587–8593PubMedCrossRefGoogle Scholar
  69. Withers HR, Taylor JMG, Maciejewski B (1988) The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 27:131–146PubMedGoogle Scholar
  70. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250PubMedCrossRefGoogle Scholar
  71. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344–352PubMedCrossRefGoogle Scholar
  72. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM (1996) Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumours given definitive irradiation. Int J Radiat Oncol Biol Phys 34:809–815PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Guido Lammering
    • 1
  1. 1.Department of Radiation Oncology and Laboratory of Experimental Radiation OncologyUniversity of MaastrichtHeerlemThe Nerlands

Personalised recommendations